Clinical Trial Update: Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma [Phase 2]

View source ↗

Summary

Pembrolizumab is being studied in a Phase II trial for recurrent or residual high-grade meningioma; results were posted in June 2023, and the trial remains acti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Meningioma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: High Grade Meningioma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-06-06